Email from TST management - November 19
Well at least they responded, even if it's a boiler plate repsonse.
Agreed that the next "PR" and communication from management will dictate how February will likely go down.
-----------------------------------------
Dear XXXX,
Thanks for writing. As you can imagine, we are receiving a lot of queries from shareholders on the meaning of the outcome of the AdComm.
As Telesta is a public listed company, I can only share with you information that is in the public domain.
In terms of general comments:
- While we are disappointed in the results of the Advisory Committee, their views are just one of the elements that the FDA takes into consideration in their approval decision.
- All but one of the practicing urologists on the panel voted Yes.
- Our PDUFA date remains February 27, 2015
- Telesta's management team, professional advisors and partners will be working very hard and diligently over the next 3 months to maximize our potential for a positive FDA decision.
Best regards,
Don
Donald Olds, M.Sc., MBA
Chief Operating Officer
Chef de l’exploitation
Telesta Therapeutics Inc.
275 avenue Labrosse
Pointe-Claire, QC
H9R 1A3
T: 514.394.7921
Hello Donald,
As a long time shareholder I have not reached out in the past however I am curious to know what your management team is planning in terms of ensuring, that despite the negative outcome yesterday, the potential approval by the FDA in early 2016 is given the maximum chance of success. I realize the precedent of a no vote by the FDA Advisory Committee doesn’t bode well traditionally in getting FDA approval.
Any information or insights you can share with me when your schedule allows would be appreciated.
Regards,
XXXX